Skin Disease Market Overview

​

 

 

 

 

 

Acne is a widespread dermatological condition that affects millions of people worldwide, spanning various age groups but peaking in adolescence and early adulthood, affecting around 85% of this group.

​

Over 50 million people in the United States alone suffer from acne each year, and the condition has a global prevalence rate of approximately 9%, making it the eighth-most prevalent disease worldwide.

​

Australia's acne therapeutics market is expected to grow from $120m in 2022 to $226m in 2030 with a CAGR of 8.2% for the forecasted year 2022-2030. More than 90% of Australian teenagers suffer from acne vulgaris which leads to the increasing demand for acne treatment options in Australia thereby driving the growth of Australia's acne therapeutics market. 

The expansive reach of acne has led to a booming market for treatment products and medications. Over-the-counter (OTC) solutions like benzoyl peroxide and salicylic acid-based cleansers, creams, and gels are readily available and are the first line of defence for mild to moderate cases.

For more severe cases, prescription medications such as isotretinoin, antibiotics, and hormonal
treatments are often recommended. Topical retinoids and azelaic acid are also commonly prescribed.

Financially, the global acne treatment market is significant and continuously growing, driven by factors like increased awareness, rising pollution levels, and lifestyle changes that contribute to acne prevalence.

Both the OTC and prescription segments contribute substantially to these numbers. Major pharmaceutical companies such as Galderma, Valeant Pharmaceuticals, and Johnson & Johnson play pivotal roles in the industry, providing a range of both OTC and prescription options.

The increasing adoption of skincare routines and growing consumer awareness about acne treatments are also contributing to the market expansion, making it a continuously evolving landscape.